Targeting MRS-Defined Dominant Intraprostatic Lesions with Inverse-Planned High Dose Rate Brachytherapy. Addendum
Final rept. 26 Jan 2008-25 May 2009
CALIFORNIA UNIV SAN FRANCISCO
Pagination or Media Count:
A combination of MRIMRSI is used to define the distribution of Dominant Intraprostatic Lesions DIL within the prostate. This information is used to perform dose escalation of the DIL without compromising the dose coverage of the prostate and the protection to the urethra, rectum, and bladder for prostate cancer patients treated with High Dose Rate HDR brachytherapy. The multi-image fusion process has been finalized during this period. The steps and criteria involved in the series of image fusions and in the planning and verification of the dose delivery process are presented. Information from one image data set to another in the series of MRS right arrow MRI right arrow CT left arrow CBCT can be accurately transferred and used for the planning and verification of the dose delivery during prostate HDR brachytherapy. Final CHR approval was obtained in 2008 and patient enrollment has begun. So far, 5 patients were treated with HDR brachytherapy with a DIL boost level of 30 or more, using the previously established class solution for the set of parameters used by the inverse planning in order to boost the dominant intra-prostatic lesion DIL defined by MRIMRSI. The DIL dose was significantly increased without any violation of standard dosimetric index requirements.
- Anatomy and Physiology
- Medicine and Medical Research